Fat Loss · 2mg × 10 vials
In plain terms: Adipotide is a research compound — oral, fast-acting and well studied.
Adipotide (also called FTPP, Fat-Targeting Proapoptotic Peptide, or Prohibitin-Targeting Peptide 1) is a synthetic chimeric peptidomimetic with two domains stitched together. The N-terminal CKGGRAKDC sequence is a vascular "homing" peptide that binds prohibitin-1 and annexin A2 receptors expressed on the endothelial cells lining the blood vessels that feed white adipose tissue. Once the peptide docks and is internalized, the C-terminal D(KLAKLAK)2 sequence (built with D-amino acids so it resists protease degradation) inserts into the mitochondrial outer membrane of those endothelial cells, disrupts membrane integrity, releases cytochrome c, and triggers caspase-driven apoptosis. The endothelial cells die, the capillary bed supplying that fat depot collapses, and the adipocytes downstream die from ischemia. The net effect is targeted destruction of the vascular scaffolding that fat needs to survive, not direct killing of fat cells themselves.
The critical problem with this mechanism, and the entire reason this compound is dangerous, is that prohibitin is NOT exclusively expressed on adipose vasculature. It is also expressed on the endothelial cells of kidney vasculature, particularly in the proximal tubule. So the same apoptotic mechanism that destroys fat capillaries also damages renal capillaries, producing tubular toxicity, proteinuria, and rising creatinine. The therapeutic window between "enough drug to kill fat vessels" and "enough drug to damage kidneys" is narrow in primates and proved unacceptable in humans.
Typical dose ranges by experience level — educational reference. Message us and we tailor it to you.
This row exists because customers ask, not because it is recommended. A first-time peptide user has no business on a compound where the FDA-registered Phase 1 trial was halted for kidney damage. Redirect to retatrutide or tirzepatide for fat loss. Adipotide is not where you start
This is the band most community self-experimenters target. At 0.5-1 mg/day a 70-80 kg adult is running roughly 0.006-0.014 mg/kg/day, which is well below the 0.43 mg/kg primate protocol but is what community users have settled on as the tolerability-vs-efficacy compromise. Expected fat loss in community reports clusters around 5-10 lbs over the cycle, mostly visceral and stubborn depots. Mandatory kidney panel pre-cycle, day 14, day 28, and 4 weeks post. Mandatory 4-6 month off-cycle before any repeat, no exceptions
At this band the renal risk profile is materially worse. The primate study showed dose-dependent renal tubular changes even at preclinical doses considered "mild and reversible", and human Phase 1 hit unacceptable nephrotoxicity at doses in this neighborhood. Anyone running 1-2 mg/day should treat this as an experimental protocol with the assumption of probable transient kidney function impairment. Lab monitoring is non-optional. The dramatic before/after photos circulating in community forums almost always come from this dose band, and the kidney complaints almost always come from this dose band as well. Both are real. There is no safe long-term protocol, only short cycles with long washouts
Straight talk — what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines — tap any to read the source.
pivotal primate study showing 10.6% weight loss and 38.7% fat loss over 28 days, with the renal toxicity signal characterized as mild and reversible
Read study ↗PubMedResponse to Comment on Peptidomimetic Targeting White Fat, Science Translational Medicine 2012Pasqualini/Arap response to early renal safety critiques
Read study ↗ClinicalTrials.govNCT01262664 — Phase I Evaluation of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesitytrial terminated, no published results
Read study ↗Physician/research summaSuperpower — A Proapoptotic Peptide Targeting Adipose Vasculatureclinical commentary on mechanism, evidence gap, and the nephrotoxicity bottleneck
Read study ↗Aggregated sentiment from public forums & socials — real-world reports, not individual endorsements.
Visible fat loss: most users report 5-10 lbs over 28 days at 0.5-1 mg/day, more at higher doses, with disproportionate loss from visceral and stubborn depots (lower belly, flanks)
Kidney concerns: a subset of users report rising creatinine, dark urine, lower back pain (kidney area), and reduced urine output during cycles. Most report values normalize within 4-8 weeks of stopping but some self-reports describe persistent eGFR drops
Fatigue: common throughout cycle, attributed to systemic apoptotic load and metabolic stress
Injection site irritation: redness, mild swelling, transient
Headaches and dehydration symptoms: common, partially controllable with aggressive hydration
Mood and energy dips: reported especially in week 3-4 of the cycle
Route: SubQ injection
Injection site: abdomen, rotate sites; some community users target stubborn fat depots directly (no evidence this improves localized vs systemic effect, the peptide circulates systemically once injected)
Storage: refrigerated, ~14-21 days after reconstitution; freshness matters because the proapoptotic D(KLAKLAK)2 sequence can lose potency if degraded
Notes: Adipotide is the highest-risk injectable in the PP catalog. Customers running it MUST baseline and monitor kidney function (serum creatinine, eGFR, BUN, urinalysis for protein/glucose) before, weekly during, and 4 weeks after the cycle. Hydration matters; running this in a dehydrated/cutting state amplifies renal stress. Daily injection on an empty stomach is the protocol most community users follow but there is no PK rationale for fasted dosing, it is just convention pulled from the primate protocol.